PRLog - Jun. 2, 2014 - Constance, Germany – GATC Biotech launches its InView™ 2-weeks Exome service and enhanced, customised epigenetic support for its more than 10,000 clients. GATC Biotech presents these and several other innovative Next Generation Sequencing (NGS) services at this year’s ESHG Annual Meeting in Milano. The new products add to GATC Biotech’s rapidly expanding InView™ portfolio of standardised NGS solutions, based on streamlined workflows providing researchers with top-quality data at a competitive pricing.
GATC Biotech´s InViewTM Epigenome will be applicable for all cell and tissue types of mammals and other relevant organisms. The products are based on bisulfite conversion with subsequent NGS (BS-Seq) or on reduced representative bisulfite sequencing (RRBS-Seq) to study the methylome at base level resolution.
“Our constant development towards streamlined NGS solutions has extended to epigenetic studies. We can apply a scalable coverage to meet every scientific requirement”, said Peter Pohl, CEO and co-founder of GATC Biotech. “In fact”, he added, “high throughput NGS is no longer only reserved for those labs with seemingly unlimited resources. Now, with InViewTM Epigenome from GATC, every researcher will have access to genome-wide epigenetic analysis.”
According to Dr. Yadhu Kumar, Head of Bioinformatics at GATC Biotech “Genome-wide analysis and bioinformatics couldn’t be easier for our customers.” As he explained, “My team of experts takes care of the raw data handling and bioinformatics analysis. So, rather than sending customers raw data, we send a GATC Data Report containing the results in a self-explanatory way and provide publishable high-quality data.”
With the launch of InView™ 2-weeks Exome, GATC Biotech addresses the market request to introduce a standardised exome sequencing solution, not available to date. As of now, researchers working in clinical research or on other time critical projects will have fast access to relevant data within 10 business days!
“We are geared up to aid in the diagnostics and prognostics of human diseases, to facilitate personalised medicine and companion diagnostics and to optimise the efficiency of individualised drug treatment, but also to support researches in a broad variety of fields including plant and animal breeding”, Peter Pohl concluded.
About GATC BIOTECH
GATC Biotech, a family-owned business is Europe’s leading service provider of DNA and RNA sequencing. For over two decades, the company has offered sequencing and bioinformatics solutions from single samples up to large scale projects. During this time, GATC Biotech has sequenced more than six million samples, ten thousands of bacterial, plant and other whole genomes, as well as hundreds of whole human genomes.
The company offers true multiplatform sequencing using all leading sequencing technologies in its own labs. Its headquarter in Constance, Germany, houses its ISO 17025 certified Genome and Diagnostics Centre with focus on Next and Third Generation Sequencing. The European Custom Sequencing Centre located in Cologne, Germany, focuses on Sanger sequencing and serves as the logistical hub within Europe. All laboratories have highly integrated and fully automated processing pipelines, ensuring full compliance with latest state-of-the-art quality standard. For more information please visit www.gatc-biotech.com.
Read Full Story - GATC Biotech extends its epigenomics and exome sequencing portfolio to researchers and physicians at the ESHG | More news from this source
Press release distribution by PRLog
GATC Biotech extends its epigenomics and exome sequencing portfolio to researchers and physicians at the ESHG
June 02, 2014 at 11:18 AM EDT
